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Abstract— In this paper, we describe a dataset relating to 
cellular and physical conditions of patients who are operated 
upon to remove colorectal tumours. This data provides a unique 
insight into immunological status at the point of tumour removal, 
tumour classification and post-operative survival. We build on 
existing research on clustering and machine learning facets of 
this data to demonstrate a role for an ensemble approach to 
highlighting patients with clearer prognosis parameters. Results 
for survival prediction using 3 different approaches are shown 
for a subset of the data which is most difficult to model. The 
performance of each model individually is compared with subsets 
of the data where some agreement is reached for multiple models. 
Significant improvements in model accuracy on an unseen test set 
can be achieved for patients where agreement between models is 
achieved. 
Keywords—ensemble learning; anti-learning; colorectal 
cancer. 
I.  INTRODUCTION  
Colorectal cancer is the third most commonly diagnosed 
cancer in the world. Colorectal cancers start in the lining of the 
bowel and grow into the muscle layers underneath then through 
the bowel wall [1]. TNM staging involves the Classification of 
Malignant Tumours  
• Tumour (T).  Size of the tumor and whether it has 
invaded nearby tissue  
• Nodes (N). The extent to which regional lymph nodes 
involved  
• Metastasis (M). This is the spread of a disease from 
one organ or part to another non-adjacent organ. 
4 TNM stages (I,II,III,IV) are generated by combining 
these three indicator levels and are allied with increasing 
severity and decreasing survival rates. 
Treatment options include minor/major surgery, 
chemotherapy, radiotherapy but the correct treatment is heavily 
dependent on the unique features of the tumour which are 
summarised by the TNM staging. Choosing the correct 
treatment at this stage is crucial to both the patient’s survival 
and quality of life. A major goal of this research is to 
automatically optimize the treatment plan based on the existing 
data. 
The data for this research was gathered by scientists and 
clinicians at City Hospital, Nottingham. The dataset we use 
here is made up of over 200 possible attributes for 462 patients. 
The attributes are generated by recording metrics at the time of 
tumour removal, these include: 
• Physical data (age, sex etc)  
• Immunological data (levels of various T Cell subsets)  
• Biochemical data (levels of certain proteins) 
• Retrospective data (post-operative survival statistics)  
• Clinical data (Tumour location, size etc).  
In the research into the relationship between immune 
response and tumour staging there has been some support of 
the hypothesis that the adaptive immune response influences 
the behavior of human tumors. In situ analysis of tumor-
infiltrating immune cells may therefore be a valuable 
prognostic tool in the treatment of colorectal cancer [2]. The 
immune and inflammation responses appear to have a role to 
play in the responses of patients to cancer [3] but the precise 
nature of this is still unclear.  
This research brings together earlier findings on the nature 
of the tumour biomarker dataset and builds an ensemble 
learning solution that offers improved predictive performance 
for a subset of patients. 
II. BACKGROUND 
The dataset supplied is a biological dataset and as such has 
a rich complement of pre-processing issues. For instance, over 
10% of the values are missing, with some attributes having 
over 40% missing values and some patients having over 30% 
missing values. Missing data poses a problem for most 
modelling techniques. One approach would be to remove every 
patient or every attribute with any missing data. This would 
remove a large number of entries, some of which only have a 
few missing values that are possibly insignificant. Another 
approach is to average the existing values for each attribute and 
to insert an average into the missing value space. The 
appropriate average may be the mean, median or mode 
depending on the profile of the data, because of this the 
handling of missing values attributes with a non-linear effect is 
particularly difficult.   
Much of the data takes the form of human analysis of 
biopsy samples stained for various markers. Rather than raw 
cell counts or measurements of protein levels we are presented 
with thresholded values. For instance, CD16 [4] is found on the 
surface of different types of cells such as natural killer, 
neutrophils, monocytes and macrophages. The data contains a 
simple 0 or 1 representing the existence or otherwise of a 
significant number of these cells rather than a count of the 
number of cells. This kind of manual inspection and 
simplification is true for most of the data and any modeling 
solution must work with this limitation.  
By using a combination of correlation coefficients and 
expert knowledge the data was reduced down to a set of ~50 
attributes.  This included removing several measurements that 
were hindsight dependent (ie. chemo or radio treatment)  and 
correlated with TNM stage. (ie. Dukes stage).  
The survival of patients with TNM class 2 and 3 tumours, 
the middle grade categories, is the most difficult to predict, 
Single attribute relationships exist within the dataset but are not 
strong. Analysis of single attributes in relation to survival can 
yield predictions with accuracy of only 59%.  
III. PREPROCESSING 
A range of preprocessing methods were applied to the data 
beyond interpolating. Some patients had extensive missing 
values, while some attributes were very poorly sampled. There 
were also some patients who’s operation was too recent or who 
had died of an unrelated cause before the success of the 
operation could be evaluated. An initial pass followed the 
following protocol: 
Removed patients with data for fewer than 50% attributes 
Removed attributes with data for fewer than 50% patients 
Removed Patients still alive but for less than 60 months 
post operation 
Removed patients who died before the 60 month survival 
threshold of unrelated reasons 
Removed TNM related attributes 
Removed post-operative attributes (eg. Radiotherapy) 
Removed derivable or correlated attributes 
Removed compound attributes       
 
Next an effort was made to convert non-linear, single attribute 
relationships into linear ones. In an effort to better represent 
attributes with non-linear effect we also converted attributes 
with non-linear effects into linear effects. FLIPL is a good 
example (figure 2), values of 0 and 3 have poorer prognosis 
for survival than 1 and 2, thereby giving a non-linear 
relationship between grade and survival. Merging the values 
for FLIPL of 0 and 3 into a new group ‘0’ and 1 and 2 into 
another group ‘1’ means that using the mean value for missing 
values now has a meaningful representation for the resulting 
modeling approach. 
 
 
Figure 2. Relationship between survival and FLIPL category 
 
A range of supervised [10] and unsupervised [11] method 
have been applied to this dataset both in predicting TNM 
classes from immune-histochemical data and predicting 
survival. The fact that an anti-learning method [10] appears to 
perform as well as any learning methods for most tasks 
suggests that there are complex behaviours at work within this 
dataset, coupled with its high dimensionality, leading to 
relatively poor prediction results. 
 
IV. SUPERVISED ENSEMBLE LEARNING OF 
SURVIVAL RATES 
The data used in this paper has detailed information about 
post-operative survival, so we can model how attribute values 
effect survival rates. For the purposes of this work a patient is 
deemed to have “survived” if they are still alive 5 years after 
their tumour removal. We initially looked at how linear 
transformation and attribute selection affected the ability to 
predict 5 year survival. Details of the neural network modeling 
approach are given later in this section but at this stage if we 
just look at the impact of this reduction in non-linearity. We 
see a much improved performance with survival prediction 
levels better than the 65% achieved by TNM alone (figure 3). 
We can also see that using the top 8 attributes selected by 
SVM attribute selection [18] provides the best performance. 
 
 
Figure 3. Prediction accuracy with an increasing number of attributes with 
and without non-linearity removal 
 
Several of the attributes presented in the dataset pertain to the 
survival of the patients after their operation to remove the 
tumour. The number of months the patient has survived, 
whether they are still alive or not and how they died (if dead) 
are all available. Figure 4 shows survival curves for patients 
up to 6 months. The strong difference between survival rates 
in TNM stage 1 and 4 patients is apparent (ie. at 30 month the 
survival rate is approximately 95% and 5% for these 2 
groups). The difference between patients with TNM stage 2 
and 3 cancers is less apparent. After 30 months deaths from 
colorectal cancer for TNM stage 1 patients increase quite 
quickly, in percentage terms steeper than any other TNM 
class. 
 
 
 
Figure 4. Survival Curves for patients at all 4 TNM stages 
 
Again focusing on just TNM stage 2 and 3 patients we 
attempted to predict survival using both AI techniques and the 
TNM stage itself. The term “survival” is somewhat subjective 
but for the purposes of this work we used 5 years as the 
threshold for survival. Using the TNM stage alone to predict 
survival gives an accuracy of 64.6% (155 correct from 240). 
This is achieved by stating that all type 2 tumour patients will 
survive and all type 3 will not. If we use the cell marker 
statistics with patient physical details (such as age and sex) we 
can achieve a slightly higher predictive performance of 65.4% 
on the unseen test by using the top 8 attributes (table 1) 
selected by SVM attribute selection [12] followed by a trained 
Neural network [4]. As well as the physical characteristic of 
age, these 8 also included T Cell levels for CD24 and Tstroma 
and chemicals such as Interleukin 17 (IL17) signalling the 
expression of certain genes such as P27.  The SVM based 
attribute selection method uses recursive feature elimination 
where the SVM is trained multiple times and the attributes 
subsequently evaluated post-training. We have already shown 
that this dataset shows anti-learning properties [8], whereby 
predicting TNM stage from immunohistochemical markers is 
best tackled using an anti-learning approach. An anti-learning 
approach [9, 10], using the bottom 6 attributes from the SVM 
attribute selection approach (table 1) achieves a 61.3% 
prediction rate. This included indicators such as the patients 
sex and levels of antibodies like clxcl10 and cxcr4. 
 
These three approaches use different attributes to perform 
their prediction and there are many inconsistencies between 
the predictions. This can be used to our advantage by 
measuring performance, in an ensemble manner, on patients 
where 2 or all 3 of the models agree. This agreement will be 
with a subset of patients so will not apply to every patient, but 
the ability to give SOME patients a BETTER prediction of 
survival is extremely valuable. Conversely, where there isn’t 
agreement the possibility of being less confident about a 
prediction could also be useful. Table 2 shows the individual 
performance of each model and also the performance when 
models agree. For example, when the simple TNM model and 
the neural network model for the top 8 attributes agree, we 
achieve a 79.2% prediction for survival. This can be viewed 
logically as: 
 
 
If Learned Neural model predicts a patient will survive 5 
years AND Patient is TNM type 2 
OR 
If Learned Neural model predicts a patient will not survive 
five years AND Patient is TNM type 3 
 THEN 
We can be ~80% confident that our prediction is correct 
 ELSE 
Patient survival cannot be predicted with any reliable 
accuracy 
 
The trained neural network used for this predictive task is 
shown in figure 5. 
 
Figure 5. Structure and weights of a survival predicting 
artificial neural network. 
 
While the non-linearity of a neural network decision making is 
notoriously difficult to glean information from, the relative 
simplicity of this neural approach means equation synthesis 
[13] yields formulas with some qualitative value, achieving 
predictive values of ~60% where models agree 
 
 
Table 1. Top 8 and bottom 6 attributes as produced  
 
 
Table 2. Accuracy of models and subsets of patients  
by SVM attribute selection [12]     
 
The dataset can now be divided into 4 distinct subgroup, each 
with a corresponding survival rate: 
 
1. TNM 2 Patients predicted to survive by the 
learning model (%) 
2. TNM 2 Patients predicted not to survive by the 
learning model (%) 
3. TNM 3 Patients predicted to survive by the 
learning model (%) 
4. TNM 3 Patients predicted not to survive by the 
learning model (%) 
One interesting observation about this is that survival of TNM 
3 patients with a positive prognosis from the model have a 
better survival rate that TNM 2 patients with a negative 
prognosis. This is shown more clearly by plotting the 4 
corresponding survival curves (fig. 6) 
 
 
Figure 6. Survival curves for 4 distinct patient sets grouped on 
TNM stage and model prognosis 
  
V. CONCLUSIONS 
We have presented results for a unique dataset based on the 
biochemical and factors associated with colorectal tumour 
patients. This dataset is limited in many ways, but extremely 
important nonetheless and modeling any relationships or 
features based on the dataset to hand is an urgent priority. 
Generally, whether attempting to predict TNM stages or 
survival, patients at TNM stage 1 and 4 have more clear 
indicators in the attribute set. TNM stage 2 and 3 provides a 
much more challenging prediction task, so much so that the 
TNM stage appears much less important when predicting 
survival for these 2 stages than other indicators. 
The dataset used here has several drawbacks when it comes 
to building robust cause-effect models. The 2 main issues are 
the missing values and the high dimensionality. By pre-
processing the dataset to convert attributes that may have a 
non-linear effect into linear attributes missing values can be 
represented as means of all values with a more stable meaning. 
This pre-processing step also makes resulting machine learning 
approach more capable of reaching global minima. The second 
issue of high dimensionality is tackled by using an attribute 
selection approach first demonstrated on another cancer 
dataset. We not only use the most highly ranked attributes here 
but by using anti-learning on the lowest ranked attributes we 
can produce a another, distinct model of the data. 
When looking specifically at survival, using 3 unique 
predictive approaches allows us to compare predictions from 
all three approaches. The amount of differences between the 3 
approaches could be inferred from the lack of relationships 
between TNM staging and the immunohistochemistry [8] and 
the lack of a relationship between unsupervised clusters and 
TNM stages [11]. So for the 240 patients, there was only 
agreement between 2 of the approaches for between 103 and 
140 patients but when agreement occurred, predictive 
performance increased up to a maximum of 82.5%. This level 
of accuracy for predicting survival of patients with TNM stage 
2 and 3 tumours is unprecedented, albeit on a small subset of 
patients. This approach offer an important opportunity for 
clinicians to improve prognosis for patients but also, any 
information gained by analysing the agreeing models can be 
fed back to researcher in their endeavours to improve treatment 
options at a cellular level. 
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